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Background
Cardiovascular disease is the leading cause of
mortality and a primary contributor to the
burden of disease worldwide (Lopez et al.
2006). Environmental toxicants, including
lead and other metals, are potentially pre-
ventable exposures that may explain popula-
tion variation in cardiovascular disease rates
(Bhatnagar 2006; Weinhold 2004). However,
after more than 100 years since initial reports
suggested a link between lead exposure and
cardiovascular outcomes (Lancéreaux 1881;
Lorimer 1886), the contribution of lead to
cardiovascular disease is still incompletely
understood. 
Population research on the cardiovascular
effects of lead has focused largely on the asso-
ciation with blood pressure and hypertension.
Several reviews and metaanalyses combining
data from more than 30 original studies and
around 60,000 participants have examined
the evidence relating blood lead to blood
pressure or hypertension [Hertz-Picciotto and
Croft 1993; Nawrot et al. 2002; Schwartz
1995; Sharp et al. 1987; Staessen et al. 1994,
1995; U.S. Environmental Protection Agency
(U.S. EPA) 2006]. All these reviews con-
cluded that there was a positive association
between blood lead levels and blood pressure
(Table 1). The estimated increase in systolic
blood pressure associated with a 2-fold
increase in blood lead levels (e.g., from 5 to
10 µg/dL) ranged across reviews from 0.6 to
1.25 mmHg. This epidemiologic relationship
is also supported by a large body of experi-
mental and mechanistic evidence (U.S. EPA
2006). Because lead exposure is widespread,
even a modest effect would imply that lead
exposure is an important determinant of
blood pressure levels and hypertension in
human populations. 
The cardiovascular effects of lead, how-
ever, are not limited to increased blood pres-
sure and hypertension. Lead exposure has
also been associated with an increased inci-
dence of clinical cardiovascular end points
such as coronary heart disease, stroke, and
peripheral arterial disease (Lustberg and
Silbergeld 2002; Menke et al. 2006; Navas-
Acien et al. 2004; Schober et al. 2006), and
with other cardiovascular function abnormal-
ities such as left ventricular hypertrophy and
alterations in cardiac rhythm (Cheng et al.
1998; Schwartz 1991). 
In the present article, our objective was to
perform a systematic review of the epi-
demiologic evidence on the association of
lead exposure with cardiovascular disease end
points. Because previous reviews have exam-
ined the connection between lead and blood
pressure in depth (Table 1), our systematic
review emphasizes other clinical and inter-
mediate cardiovascular outcomes to obtain a
broader picture of the impact of lead on car-
diovascular disease. Finally, we assessed the
causal role of lead on blood pressure and car-
diovascular disease by applying the criteria
and terminology of the 2004 Surgeon
General Report The Health Consequences of
Smoking [U.S. Department of Health and
Human Services (U.S. DHHS) 2004] to the
available information.
Methods
Search strategy and data abstraction. We
aimed to identify all observational studies
assessing the association between lead expo-
sure and cardiovascular end points. Using free
text and key words (Appendix A), we searched
PubMed (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=PubMed), EMBASE
(http://www.embase.com/), and TOXLINE
(http://toxnet.nlm.nih.gov/) through August
2006 with no language restrictions. In addi-
tion we manually reviewed the reference lists
from relevant original research and review arti-
cles and documents. 
For lead exposure, we included studies
that used biomarkers (lead levels in blood,
bone, or other specimens), environmental
measures (airborne lead levels), or indirect
measures (job titles, job exposure matrices, liv-
ing in lead-contaminated areas). For cardio-
vascular end points, we included studies that
reported clinical cardiovascular end points
(cardiovascular disease, coronary heart disease,
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OBJECTIVE: This systematic review evaluates the evidence on the association between lead exposure
and cardiovascular end points in human populations.
METHODS: We reviewed all observational studies from database searches and citations regarding
lead and cardiovascular end points. 
RESULTS: A positive association of lead exposure with blood pressure has been identiﬁed in numer-
ous studies in different settings, including prospective studies and in relatively homogeneous
socioeconomic status groups. Several studies have identiﬁed a dose–response relationship. Although
the magnitude of this association is modest, it may be underestimated by measurement error. The
hypertensive effects of lead have been confirmed in experimental models. Beyond hypertension,
studies in general populations have identiﬁed a positive association of lead exposure with clinical
cardiovascular outcomes (cardiovascular, coronary heart disease, and stroke mortality; and periph-
eral arterial disease), but the number of studies is small. In some studies these associations were
observed at blood lead levels < 5 µg/dL. 
CONCLUSIONS: We conclude that the evidence is sufficient to infer a causal relationship of lead
exposure with hypertension. We conclude that the evidence is suggestive but not sufﬁcient to infer
a causal relationship of lead exposure with clinical cardiovascular outcomes. There is also suggestive
but insufﬁcient evidence to infer a causal relationship of lead exposure with heart rate variability. 
PUBLIC HEALTH IMPLICATIONS: These ﬁndings have immediate public health implications. Current
occupational safety standards for blood lead must be lowered and a criterion for screening elevated
lead exposure needs to be established in adults. Risk assessment and economic analyses of lead expo-
sure impact must include the cardiovascular effects of lead. Finally, regulatory and public health
interventions must be developed and implemented to further prevent and reduce lead exposure.
KEY WORDS: atherosclerosis, blood pressure, cardiovascular disease, heart rate variability, hypertension,
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mediate cardiovascular end points (left ven-
tricular mass, heart rate, heart rate variability,
or electrocardiographic abnormalities) other
than blood pressure levels or hypertension. 
We excluded publications containing no
original research, studies not carried out in
humans, case reports, case series, ecologic
studies, studies lacking a cardiovascular out-
come, and studies lacking data on lead expo-
sure (Figure 1). For studies with multiple
publications on the same population, we
selected the publication with the longest fol-
low-up. For studies with equivalent follow-up
periods, we selected the study with the largest
number of cases or the most recent publica-
tion. We excluded autopsy studies measuring
lead in arterial tissue and studies based on
polycardiography and ballistocardiograpy,
techniques no longer in use. For consistency,
blood lead levels were converted to micro-
grams per deciliter. 
We adapted the criteria used by
Longnecker et al. (1988) to assess study qual-
ity for studies of clinical end points and the
criteria used by Appel et al. (2002) to assess
study quality for studies of intermediate end
points (Appendices B and C). 
Statistical methods. Measures of association
(odds ratios, prevalence ratios, standardized
mortality ratios, relative risks, relative hazards,
comparisons of means, linear regression coefﬁ-
cients, correlation coefﬁcients) and their stan-
dard errors were abstracted or derived from
published data (Greenland 1987). For studies
reporting measures of association for popula-
tion subgroups (Cooper et al. 1985; Malcolm
1971), we pooled the measures of association
using an inverse-variance weighted random-
effects model (Egger et al. 2001). 
Because of substantial heterogeneity and
methodologic limitations of the original
studies, we considered that quantitative pool-
ing was inappropriate. We thus present a
qualitative systematic review of the available
evidence.
Results
Lead and clinical cardiovascular disease in
general populations. Twelve studies met our
inclusion criteria (Table 2). Lead was meas-
ured in blood in all the prospective cohort
studies (Kromhout 1988; Lustberg and
Silbergeld 2002; Menke et al. 2006; Møller
and Kristensen 1992; Pocock et al. 1988)
and in the only cross-sectional study available
(Muntner et al. 2005). Blood lead levels were
substantially lower in more recent compared
with older studies. Case–control studies
assessed lead exposure on the basis of lead
levels in blood (Kosmala et al. 2004), plasma
(Mansoor et al. 2000), and urine (Pan et al.
1993; Tsai et al. 2004), on a job exposure
matrix (Gustavsson et al. 2001), and on lead
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Table 1. Reviews of the association between blood lead levels and blood pressure.
Year of Median of 
No. of publication  Language  Total Age range of Pooled estimate estimates
studies of studies of literature  no. of  participants [change in mmHg  [change in mmHg  Conclusions as 
First author, year Typea included (range) search subjects (years) Comparison Outcome (95% CI)] (range)] reported by authors
Sharp et al.  Review 4 1982–1986 English, French 8,406 24–59 Per 2-fold ↑b SBP — 1.9 (0.7 to 2.3)  Evidence consistent 
1987 with causation
Hertz-Picciotto Review 13 1980–1992 English 22,923 12–80 ≠ for each SBP — 2.0 (–5.9 to 8.0) Evidence strongly 
and Croft 1993 study DBP — 1.7 (–1.6 to 4.0) supports causal
Hypertension — RR: 1.4 (1.2 to 1.7) association
Staessen et al. SR, MA 23 1980–1993 English, French,  33,141 10–88 Per 2-fold ↑ SBP 1.0 (0.4–1.6)  1.0 (–3.0 to 14.0) MA suggests a weak
1994, 1995 German DBP 0.6 (0.2–1.0) 1.0 (–2.0 to 13.0) association
Schwartz 1995 SR, MA 15 1985–1993 English NR 18–76 Per 2-fold ↑b SBP 1.25 (0.87–1.63)  1.45 (0.2 to 3.2) MA consistent with 
Men only causal association
ATSDR 1999 SR 24 1980–1996 No language NR All ages ≠ for each SBP — NR Suggestion of ↑ blood
restriction study DBP — NR pressure, but evidence
Hypertension — NR is inconclusive
Nawrot et al.  SR, MA 31 1980–2001 English, French,  58,518 10–90 Per 2-fold ↑ SBP 1.0 (0.5–1.4) 1.0 (–5.0 to 14.0)  MA suggests a weak 
2002 German DBP 0.6 (0.4–0.8) 1.0 (–2.0 to 14.0) association
U.S. EPA 2006 SR, MA 9 1990–2003 English 27,424 14–93 Per 2-fold ↑ SBP 0.81  (0.46–1.16)c 1.0 (–3.9 to 11) MA suggests an effect
10 34,740 DBP — 1.0 (–1.3 to 7.3) of blood lead on SBP
Abbreviations: ≠, different; ↑, increase; CI, conﬁdence interval; DBP, diastolic blood pressure; MA, meta-analysis; NHANES, National Health and Nutrition Examination Survey; NR, not reported;
RR, relative risk; SBP, systolic blood pressure; SR, systematic review; U.S. DHHS, U.S. Department of Health and Human Services; U.S. EPA, U.S. Environmental Protection Agency.
aSystematic review: a search strategy and criteria for manuscript selection are speciﬁed. Meta-analysis: a pooled analysis using meta-analysis techniques are presented. bIn the study by
Sharp et al. (1987), we divided by 3 the change per 15 µg/dL (equivalent to comparing 10 µg/dL vs. 5 µg/dL). The study by Schwartz et al. (1995) reports the change in mmHg comparing
10 µg/dL vs. 5 µg/dL. cPooled estimate using an inverse variance weighted random-effects model (Egger et al. 2001) of two pooled estimates for linear and log-linear estimates, respectively.
Figure 1. Flow diagram of study selection process. Databases: PubMed (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=PubMed); EMBASE (http://www.embase.com/); TOXLINE (http://toxnet.nlm.nih.gov/). 
Distinct references identified (n = 3,093)
PubMed search: 2,177
EMBASE (not PubMed): 425
TOXLINE (not PubMed /EMBASE): 466
Hand search: 25
References excluded (n = 3,019)
No original data or no human research
Case series, case reports, ecologic studies
No data on lead exposure
No cardiovascular outcome; autopsy
  outcome; polycardiography or
  ballistocardiography based outcomes
Studies of lead and blood pressure
Distinct reference (n = 74)
References excluded (n = 12)
Multiple publications from same population:
General populations: 3
Occupational populations: 9
Other cardiovascular end points: 1
Clinical cardiovascular end points (n = 30)
General populations: 12
Occupational populations: 18
Intermediate cardiovascular end points (n = 32)
Ventricular mass/function: 5
Heart rate variability: 11
Other cardiac end points: 15
Other vascular end points: 1levels in the air of the residential neighbor-
hood of study participants (Dulskiene 2003).
None of these studies determined lead in
bone. Although cohort studies and the cross-
sectional study tended to fulfill prespecified
quality criteria, case–control studies failed to
fulfill some important quality criteria
(Appendix B). 
Lead exposure was positively associated
with clinical cardiovascular end points in all
studies (Table 2). Among prospective studies,
the relative risks for coronary heart disease
ranged between 1.1 comparing blood lead
levels > 24.8 µg/dL versus < 12.4 µg/dL in the
British Regional Heart Study (Pocock et al.
1988) and 1.89 comparing blood lead levels
≥ 3.63 µg/dL versus < 1.93 µg/dL in the
National Health and Nutrition Examination
Survey (NHANES) III Mortality Follow-up
Study (Menke et al. 2006). The relative risk
for stroke in the NHANES III Mortality
Follow-up Study was 2.51. There were no
prospective studies on the association of
blood lead with peripheral arterial disease.
However, the relative risk for peripheral arter-
ial disease comparing blood lead levels
≥ 2.47 µg/dL versus < 1.03 µg/dL in a cross-
sectional analysis of NHANES 1999–2002
was 1.92 (Muntner et al. 2005). 
Lead and cardiovascular mortality in occu-
pational populations. Eighteen studies from the
United States (Cooper et al. 1985; Michaels
et al. 1991; Robinson 1974; Sheffet et al. 1982;
Steenland et al. 1992; Tollestrup et al. 1995),
Europe (Alexieva et al. 1981; Belli et al. 1989;
Carta et al. 2003; Cocco et al. 1997, 1994;
Davies 1984; Dingwall-Fordyce and Lane
1963; Gerhardsson et al. 1995; Lundstrom
et al. 1997; Malcolm 1971; Wilczynska et al.
1998), and Australia (McMichael and Johnson
1982) met our inclusion criteria (Table 3).
Battery, ceramic, pigment, reﬁnery, and smelter
industries were studied. All studies used job
titles to ascertain exposure and death certiﬁcates
to identify coronary heart disease (12 studies),
stroke (15 studies) and overall cardiovascular
mortality (9 studies). Most were retrospective
cohort studies and used external comparisons to
the general population to derive standardized
mortality ratios. The exceptions were the study
by Dingwall-Fordyce and Lane (1963), two
Navas-Acien et al.
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Table 2. Epidemiologic studies of lead exposure and clinical cardiovascular disease in general populations.
First author, Men Age range  Lead Range of End point No. of cases/ Measure ofb
year Country Population (%) (years)  assessment lead levels ascertainment Outcome noncases association Comparison Adjusted forc
Prospective cohort studies
Pocock et al.  U.K. British Regional 100 40–49 Blood < 6.2 to Death certiﬁcate CHD, F + NF 316/7,063 OR 1.1 (0.4–1.8) > 24.8 vs. Age, smoking, 
1988 Heart Study (AAS) > 35.2 µg/dL or chest pain,  < 12.4 µg/dL location
enzyme, ECGa
Death certiﬁcate, Stroke,  66/7,313 Mean 16.7 µg/dL Cases vs.  Age, smoking, 
medical record F + NF Mean 15.3 µg/dL noncases location
Kromhout  Nether- Elderly men in 100 57–76 Blood < 10.8 (10th p) Death certiﬁcate CHD, F + NF 26/115 HR 1.34 (0.46–3.94) > 23.8 vs. Age, smoking, BMI, 
1988 lands  Zutphen  (AAS)  > 28.0 (90th p) or chest pain, < 13.0 µg/dL  BP, cholesterol
µg/dL enzyme, ECGa
Møller and Denmark Survey repondents 48 40 Blood 2 to 60 µg/dL Death certiﬁcate, CHD, F + NF 40/1,005 HR 1.58 (0.85–2.95) Per log unit  Sex, smoking, alcohol, 
Kristensen  4 municipalities (AAS) hospital  CVD, F + NF 54/991 HR 1.10 (0.63–1.93) change  BP, cholesterol, 
1992 admissions exercise
Lustberg and U.S. NHANES II 47 30–74 Blood < 10 to 29  Death certiﬁcate CVD, F 424/3,766 HR 1.39 (1.01–1.91) 20–29 vs. Age, sex, race, educ.,
Silbergeld (AAS) µg/dL <  10  µg/dL  income,  smoking, 
2002 BMI, exercise, 
location
Menke et al.  U.S. NHANES III 47 ≥ 17 Blood < 1 to 10 Death certiﬁcate CVD, F 766/13,198 HR 1.55 (1.08–2.24) < 1.93 vs.  Age, sex, race, educ., 
2006 (AAS) µg/dL CHD, F 367/13,597 HR 1.89 (1.04–3.43) ≥ 3.63 µg/dL income, smoking, 
Stroke, F 141/13,823 HR 2.51 (1.20–5.26) alcohol, BMI, 
exercise, cholesterol,
CRP, urban 
residence, 
menopause, 
hypertension, 
kidney function
Case–control and cross-sectional studies
Pan et al.  Taiwan Clinic-based 69 NR Urine 7.9 to 138.4 NR BFD prev. 16/16 30.8 (30.1) µg/L Cases vs. Age, sex
1993 (DPASV) µg/L 17.4 (5.4) µg/L noncases
Mansoor  Sweden Clinic-based 53 Mean Plasma Mean Angiograms PAD prev. 65/65 3.3 (0.4) ng/g plasma Cases vs. Age, sex
et al. 2000 46 (TRXFS) 3.3 ng/g plasma 3.2 (0.3) ng/g plasma noncases
Gustavsson  Sweden SHEEP Study 68 45–70 JEM NM Chest pain, ECG AMI inc., 1,335/1,658 OR 1.03 (0.64–1.65) ≥ 0.04 mg/m3  Age, sex, smoking, 
et al. 2001 enzymea NF vs. unexp. alcohol, BP, BMI, 
exercise, location
Dulskiene  Lithuania Clinic-based 100 25–64 Airborne NM Medical records AMI 579/1,777 OR 1.12 (0.76–1.40) > 0.225 vs. Age, sex, smoking, 
2003 ≤ 0.225 µg/m3 BP
Tsai et al.  Taiwan Clinic-based 57 NR Urine 5.3 to 123.6 NR BFD prev. 68/68 33.7 (24.3) µg/L  Cases vs.  Age, sex
2004 (AAS) µg/L 22.2 (11.8) µg/L noncases
Kosmala  Poland Clinic-based 53 Mean Blood Mean Coronariography, Effort angina 33/18 3.9 (1.4) µg/dL Cases vs.  Crude
et al. 2004 62 (AAS) 3.9 µg/dL  treadmill  3.7 (1.2) µg/dL noncases
exercise text 
Muntner U.S. NHANES  47 ≥ 40 Blood < 0.3 to  Ankle-brachial PAD prev. NR  OR 1.92 (1.02–3.61) ≥ 2.47 vs. Age, sex, race, 
et al. 2005 1999–2002 (AAS) > 10 (98th p)  BP index < 1.06 µg/dL  educ., insurance, 
µg/dL smoking, alcohol,
BMI, diabetes 
Abbreviations: AAS, atomic absorption spectrometry; AMI, acute myocardial infarction; BFD, black foot disease, a form of peripheral arterial disease endemic in the arseniasis areas of
southwestern Taiwan; BMI, body mass index; BP, blood pressure levels or hypertension; CHD, coronary heart disease; CI, conﬁdence interval; CVD, cardiovascular disease; DPASV, dif-
ferential pulse anodic stripping voltammetry; ECG, electrocardiogram; educ., education; F, fatal; F+NF, fatal and nonfatal; HR, hazard ratio; inc., incidence; JEM, job exposure matrix; NF,
nonfatal; NHANES, National Health and Nutrition Examination Survey; NM, not measured; NR, not reported; OR, odds ratio; PAD, peripheral arterial disease; p, percentile; prev, preva-
lence; SHEEP, Stockholm Heart Epidemiology Study; TRXFS, total-reﬂection X-ray ﬂuorescence spectrometry; unexp., unexposed.
aStandard World Health Organization criteria for myocardial infarction. bFor studies that categorized lead exposure, we report the HR or OR (with 95% CI in parentheses) comparing the
highest with the lowest lead category. Otherwise, we present the mean (SD) lead levels for cases and noncases. cBlood pressure–unadjusted relative risk is as follows: a) Menke (2006):
cardiovascular mortality 1.64, coronary heart disease mortality 2.01, stroke mortality 2.61; b) Gustavsson( 2001): acute myocardial infarction 1.17.proportional mortality studies (Alexieva et al.
1981; McMichael and Johnson 1982) and two
prospective cohort studies (Robinson 1974;
Tollestrup et al. 1995). Occupational studies
failed to fulﬁll most prespeciﬁed quality criteria
(Appendix B). 
Relative risk estimates across occupational
studies varied widely, with positive, inverse,
and null associations (Table 3). Several stud-
ies reported the associations among workers
with the heaviest exposure (Dingwall-Fordyce
and Lane 1963; Lundstrom et al. 1997;
Malcolm and Barnett 1982; Steenland et al.
1992), by year of hire (Cooper et al. 1985;
Lundstrom et al. 1997), and incorporating a
latency period (Lundstrom et al. 1997). In
two of the three studies that reported associa-
tions by duration of employment, coronary
Lead exposure and cardiovascular disease
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Table 3. Epidemiologic studies of cardiovascular mortality in occupational populations exposed to lead.
Corrected 
Men Age range Follow-up No. of for healthy 
First author, year Country Population (%) (years)  Outcome (years) deathsa RR (95% CI)b Comparison  Adjusted for worker effect
Prospective cohort studies
Robinson 1974 U.S. Tetraethyl lead 100 20–58 CVD 20 57  0.64 (0.54–0.75) Production vs. Crude No
production workers n = 1,252 maintenance workers 
Tollestrup et al. U.S. Orchard workers 66 8 to CHD 45 NR 1.27 (0.72–2.23) Workers vs. Age, sex No
1995 (lead arsenate) ≥ 55 Stroke NR 0.82 (0.31–2.12) general population
n = 1,097
Retrospective cohort studies
Dingwall-Fordyce U.K. Lead pensioners 100 ≥ 65 Stroke 35 51 2.73 (1.31–5.71)c Assembly, plumbers, Age, period No
and Lane 1963 and workers Mean 55 plate cutting, etc. vs. 
ofﬁce, chemist, etc.
Malcolm 1971, U.K. Lead battery and 99 < 65 to CHD  10 99 1.00 (0.82–1.22)  Workers vs.  Age No 
Malcolm and smelter pensioners ≥ 65 at general population
Barnett 1982 and workers death Stroke 51 103 1.31 (0.66–1.91) High exposed
vs. no exposed
Sheffet et al.  U.S. Pigment plant 100 Mean CVDd 31 139 0.62 (0.52–0.73) Workers vs. 
1982 workers 27.8 general  population
Davies 1984 U.K. Pigment plant 100 18–59 Stroke 30 31 0.94 (0.66–1.33) Workers vs. Age, period No
workers general population
Pigment plant 100  18–59 Stroke  30 9 4.10 (2.12–7.86)  Workers vs. Age, period No
workers + lead general population
poisoning
Cooper et al.  U.S. Lead battery and 100 < 25–74 CVD 24 984 0.97 (0.99–1.06)  Workers vs. Age (~ ﬁndings by year of  Partiallye
1985 producing workers CHD 715 0.85 (0.69–1.05) general population hire and employment 
Stroke 172 1.06 (0.76–1.48) duration)
Belli et al. 1989 Italy Lead miners 100 NR CVD 36 82 0.95 (0.76–1.10) Workers vs. Age No
general population
Michaels et al. U.S. Newspaper print 100 19–83 CHD 23 186 0.63 (0.54–0.73) Workers vs. Age (for stroke, analysis  Partially 
1991 workers Stroke 43 1.35 (0.98–1.82)  general population by employment durationf) 
Steenland et al. U.S. Smelter workers 100 NR CHD 39 320 0.94 (0.84–1.05) Workers vs. Age, period (+ analyses  Partially 
1992 Stroke 74 1.05 (0.82–1.32) general population by employment durationg)
CHD 39 239 0.99 (0.87–1.12) High exposed vs. Age, period
Stroke 53 1.05 (0.79–1.37) general population
Cocco et al. 1994 Italy  Lead miners 100 Mean CVD 28 258 0.63 (0.56–0.72) Workers vs. Age, period (~ ﬁndings for  No
27.7 general population surface and underground 
workers) 
Gerhardsson  Sweden Smelter workers 100 NR CHD 20 34 1.72 (1.20–2.42) Workers vs. Age, period (~ ﬁndings by No
et al. 1995 Stroke 0  0 (0.00–1.23) general population year of hire)
Lundström et al. Sweden Smelter workers 100 15 to CVD 32 234 0.90 (0.80–1.00) Workers vs. Age, period (~ ﬁndings for  No
1997 ≥ 75 at CHD 152 0.80 (0.70–1.00) general population highest exposure group and
death Stroke 36  0.80 (0.60–1.20) adding a latency period)
Cocco et al. 1997 Italy Smelter workers 100 Mean CVD 48 251 0.70 (0.62–0.80) Workers vs. Age, period No
30.4 CHD 49  0.34 (0.25–0.45) general population
Stroke 105 0.95  (0.77–1.15)
Wilczynksa et al. Poland Workers  100 < 29 to CVD 22 231 0.91 (0.80–1.04) Workers vs. Age (~ ﬁndings by number  No
1998 compensated for  ≥ 50 at 1st  CHD 98 0.96 (0.78–1.17) general population of lead poisoning
lead poisoning episode Stroke 33 1.03 (0.71–1.45) episodes)
Carta et al. 2003 Italy Smelter workers 100 NR CVD 29 28 0.80 (0.56–1.16) Workers vs. Age No
general population
Proportional mortality study
Alexieva et al. Bulgaria Smelter workers 100 Mean CHD  10 26 5.60 (1.68–18.6) Workers vs.  Age No
1981 at death  Stroke 47 0.17 (0.08–0.36) general population
61
McMichael and Australia Smelter workers 100 30 to CHD 40 231  0.95 (0.67–1.35) Exposed workers Age No
Johnson 1982 > 60 at Stroke 53  1.45 (0.76–2.76) vs. staff workers
death
Abbreviations: CHD, coronary heart disease; CI, conﬁdence interval; CVD, cardiovascular; RR, relative risk; SMR, standard mortality ratio. 
In all studies, lead exposure was determined through job titles, and mortality outcomes were assigned through information in death certiﬁcates. aSample size not available in most studies.
bRelative risk estimates came from SMRs except Robinson (1974) (RR), Tollestrup (1995) (HR), Alexieva (1981) (proportional mortality rate), and McMichael (1982) (proportional mortality
rate). cThe within-cohort relative risk was estimated by comparing standardized mortality ratios in the highest versus the lowest category of exposure. dA total of 15% of subjects with
unknown cause of death in death certiﬁcate. ePartial adjustment indicates that authors conducted additional analyses by employment duration. fFor Michaels et al. (1991), SMRs (95%CI)
for stroke by number of years of employment are < 10 years, 2.52 (0.06–13,93); 10–19 years, 0.32 (0.01–1.74); 20–29 years, 0.65 (0.18–1.68); ≥ 30 years, 1.68 (1.18–2.31). gFor Steenland et al.
(1992), SMRs by numbers of years of employment are as follows: a) CHD: 1–5 years, 1.02; 5–20 years, 0.92; ≥ 20 years, 0.86. b) Stroke: 1–5 years, 0.83; 5–20 years, 1.01; ≥ 20 years, 1.41.heart disease (Steenland et al. 1992) and
stroke (Michaels et al. 1991) mortality were
higher among workers with the highest num-
ber of years of employment. 
Lead and intermediate cardiovascular
outcomes. Five studies evaluated ventricular
wall dimensional and functional parameters
(Beck and Steinmetz-Beck 2005; Kasperczyk
et al. 2005; Schwartz 1991; Tepper et al.
2001; Zou et al. 1995) (Table 4). Increased
blood lead levels were associated with an
increased prevalence of left ventricular hyper-
trophy in U.S. adults (Schwartz 1991) and
with a nonstatistically significant increase in
left ventricular mass in U.S. battery workers
(Tepper et al. 2001). Similarly, Polish steel
workers had higher left ventricular mass
and lower ejection fraction compared to
administrative workers from the same factory
(Kasperczyk et al. 2005), and lead-exposed
Polish workers had impaired diastolic function
compared with nonexposed controls (Beck
and Steinmetz-Beck 2005). Chinese refinery
workers with blood lead levels > 50 µg/dL had
similar interventricular septum and left ven-
tricular wall thickness compared to workers
< 50 µg/dL (Zou et al. 1995), although lead
levels in the reference category are unknown. 
Ten studies measured heart rate variabil-
ity among lead-exposed workers (Andrzejak
et al. 2004; Böckelmann et al. 2002; Gajek
et al. 2004; Gennart et al. 1992; Ishida et al.
1996; Murata et al. 1995; Murata and Araki
1991; Muzi et al. 2005; Niu et al. 1998;
Teruya et al. 1991), and one study measured
heart rate variability in Seoul, Korea, public
officials not occupationally exposed to lead
(Jhun et al. 2005) (Table 4). Most of these
studies had limitations in terms of sample
size, methods of lead assessment, and lack of
adjustment for potential confounders
(Table 4; Appendix C). The conditions for
electrocardiographic ascertainment and the
heart rate variability indices differed widely
across studies, making comparisons difﬁcult.
Navas-Acien et al.
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Table 4. Epidemiologic studies of lead exposure and intermediate cardiovascular end points.
Age Lead Range
First author, Sample Men range assess- levels End point
year Country Population size (no.) (%) (years) ment (µg/dL) Comparison ascertainment Main ﬁndings
Studies of ventricular mass and function
Schwartz U.S. NHANES II < 9,932 ~ 50 25–74 Blood NR Per 1 µg/dL ECG (Minnesota code) ↑ prevalence left ventricular hypertrophy 
1991 OR adjusted for age, sex, race = 1.33 (95% CI, 1.09–1.61) 
Zou et al. China Reﬁnery workers 41 81 24–45 Blood Mean > 50 vs.  US (dimensional  ~ end-diastolic, systolic internal dimension, wall thickness
1995 42.5 < 50 µg/dL and functional  ~ ejection fraction (%), cardiac output (mL/sec), 
parameters) index (mL/sec × m2
~ heart rate
Tepper et al. U.S. Battery workers 108 51 36–73 Blood 12–50 34–50 vs. US and ECG ↑ left ventricular mass (g/m2) but NS (p = 0.20)
2001 12–25 µg/dL
Kasperczyk Poland Steel workers  143 NR Mean Blood Mean Administrative US (dimensional ↑ left ventricular mass (g and g/m2) 
et al. 2005 44 23.4 workers and functional  ↑ left, ~ right end-diastolic internal dimensions 
parameters) ~ wall thickness (interventricular septum, posterior wall, others)
↓ ejection fraction (%)
Beck and Poland Lead workers 104 100 32–56 Blood 19.3–79.8 Lead exposed Echo-doppler  ↓ early mitral inﬂow peak velocity, ↑ late mitral inﬂow 
Steinmetz- vs. control peak velocity
Beck 2005 ↓ time velocity integral of early vs. late diastolic inﬂow
~ time velocity integral of early vs. total diastolic inﬂow
↑ time velocity integral of late vs. total diastolic inﬂow
~ Isovolumetric relaxation time of left ventricle
Studies of heart rate variability
Murata and Japan Gun workers 32 100 23–58 Job title < 16–60 Other workers ECG: 100 R-R intervals,  ↓ CV of R-R interval; ~ CV of LF component, 
Araki 1991 no lead exp. normal breath ↓ CV of HF component
Teruya et al. Japan Battery, reﬁnery 172 100 18–57 Blood 5–76 Correlation, ECG: 1 min, normal,  ~, ↓ mean; ~, ↓ SD; and ~, ↓ CV of R-R interval 
1991 workers > 50 vs. deep breath ~, ↓ maximal variation ratio (min/max R-R interval)
< 20 µg/dL ~, ↓ maximal variation rate ([min/max R-R interval]/mean)
Gennart  Belgium Battery workers  183 100 22–55 Blood 4.4–75 Other workers ECG: normal, deep  ~ CV of R-R interval, ~ CV of mean square of successive 
et al. 1992 (ﬁnishing, main- breath differences, and ~ CV of mean ratio of shortest to longest R-R
tenance, etc.)
Murata  Japan Glass workers 51 0 21–35 Job title NR Textile  ECG: 100 R-R intervals, ~ heart rate
et al. 1995 workers normal breath ↓ CV of R-R interval, ↓ CV of LF and ↓ HF components
↓ LF/HF ratio
Ishida et al. Japan  Ceramic painters 128 45 29–75 Blood 2.1–69.5 > 30 vs.  ECG: 100 R-R intervals, ~ CV of R-R interval
1996 < 10 µg/dL normal, deep breath
Doppler: ﬁnger blood  ↓ ﬂow between supine and standing/supine 
ﬂow ~ ﬂow drop velocity (supine ﬂow/time to the nadir after standing)
Niu et al. China Lead-exposed 302 NR 20–59 Job title NM Healthy  ECG: deep breath, ~ R-R interval 
1998 workers controls valsalva, stand up
Böckelmann Germany Lead, iron, steel  136 100 Mean Blood Mean lead  Iron steel ECG: 90 min, ↓ heart rate at rest
et al. 2002 workers 43 workers workers 10-step battery test ↑ sinus arrhythmia at rest
31.2 Lack of recovery of LF and HF after test
Gajek et al. Poland Foundry workers 35 100 Mean Blood < 3.6 to Healthy  ECG: 24 hr, long- ~ mean R-R, SDNN, SDNN index, SDANN, rMSSD, pNN50 
2004 42 > 41.0 controls and short-term  Short-term only: ~ TP, VLF, LF, HF, LF/HF, HF night / HF day
Andrzejak Poland Copper smelter 86 100 Mean Blood Mean lead Healthy controls ECG: 24 hr ~ heart rate
et al. 2004 workers 43 workers matched on age, Long-term: ↓ pNN50, ~ mean R-R, SDNN, SDNN index, 
46.8 sex, smoking, SDANN, rMSSD
lipids, BMI  Short-term: all parameters ↓ included LF and HF, except mean 
R-R and LF:HF
Muzi et al. Italy Battery workers 78 96 Mean Blood < 3.5 to  Other workers ECG: battery tests ↓ R-R interval ratios for lying-standing, lying-standing-lying, 
2005 38 > 31.6 deep breaths, and valsalva
Jhun et al. Korea Public ofﬁcials 331 55 Mean Blood < 1.39 to Per natural-log ECG: 3 min, ↓ LF, HF, and total power spectrum
2005 and family 38 > 3.45 unit seated position
Continued, next pageThe coefficient of variation of the R-R
interval was lower in lead-exposed workers
compared with other workers in two of five
studies in which the coefficient of variation
was measured under normal breathing, and
in one of three studies in which it was
assessed during deep breathing. Among
Seoul public officials (Jhun et al. 2005),
increased lead levels were inversely associated
with measures of low frequency, high fre-
quency, and total power spectrum in uni-
variate analyses, but adjusted results were
not presented because lead exposure was
dropped from the stepwise regression
models used. 
Fifteen studies reported the association of
lead with other electrocardiographic parame-
ters (Cheng et al. 1998; Gatagonova 1995a,
1995c; Kirkby and Gyntelberg 1985;
Kosmider 1968; Kosmider and Petelenz
1961, 1962; Kosmider et al. 1965; Kromhout
et al. 1985; Krotkiewski et al. 1964; Saric
1981; Shcherbak 1988; Sroczynski et al.
1990, 1985; Stozinic and Colakovic 1980)
and one study with other vascular abnormali-
ties (Aiba et al. 1999). All studies, except the
Normative Aging Study (Cheng et al. 1998),
were conducted in occupational populations
in Europe. These types of outcome, including
rhythm disorders, ischemic changes and cycle
duration, varied widely across studies, and the
findings were inconsistent. The Normative
Aging Study measured lead in blood, tibia,
and patella and identified associations
between tibia lead and intraventricular con-
duction defects (QRS duration) and increased
QT duration in subjects < 65 years of age
(Cheng et al. 1998). 
Finally, heart rate was evaluated using dif-
ferent methods in five studies, four in lead-
exposed workers (Böckelmann et al. 2002;
Kosmider and Petelenz 1961; Murata et al.
1995; Zou et al. 1995) and one in elderly
men from the Netherlands (Kromhout et al.
1985), with inconsistent ﬁndings. 
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Table 4. Continued.
Age Lead Range
First author, Sample Men range assess- levels End point
year Country Population size (no.) (%) (years) ment (µg/dL) Comparison ascertainment Main ﬁndings
Studies of other cardiac function abnormalities
Kosmider and Poland Lead-poisoned  140 100 18–45 Job title NM Healthy controls ECG ↓ heart rate, ↓ P-Q interval 
Petelenz workers symptoms ↑ heart muscle lesions and vegetative disorders
1961
Kosmider and Poland Lead-poisoned 76 100 46–65 Job title NM Healthy controls ECG ↑ heart muscle lesions and vegetative disorders
Petelenz workers symptoms
1962
Krotkiewski Poland Lead-poisoned 591 78 20–68 Job title NM Other workers ECG ↑ prevalence of ischemic changes: 32% vs. 13% 
et al. 1964 workers symptoms
Kosmider  Poland Lead-poisoned 100 100 20–45 Job title NM Healthy controls ECG ↑ heart muscle lesions and vegetative disorders 
et al. 1965 workers symptoms
Kosmider Poland Lead-poisoned 216 100 18–65 Job title NM Healthy controls ECG ↑ heart muscle lesions and vegetative disorders
1968 workers symptoms
Stozinic and Yugosla- Lead-poisoned 1,000 100 NR Job title NM Healthy controls ECG questionnaire ↑ electrocardiographic abnormalities (including ↑ S-T segment) 
Colakovic via workers symptoms ↑ self-reported coronary heart disease and intermittent 
1980 claudication
Saric 1981 Croatia Residents near  502 50 26–70 Area of  NM Residents far  ECG ~ electrocardiographic abnormalities
to and far from  residency from smelter
a smelter
Kromhout Nether- Elderly men 152 100 57–76 Blood < 10.8 Correlation  ECG ~ resting heart rate
et al. 1985 lands in Zutphen > 28.0
Kirkby and Denmark Lead smelter 190 89 30–60 Job title Mean 31 Healthy controls ECG (Minnesota code) ↑ prevalence of ischemic changes: 20% vs. 6%
Gyntelberg workers residents in 
1985 Glostrup
Sroczynski Poland Lead workers 250 100 Mean Job title NM Other workers ECG (Minnesota code) ↑ prevalence of ischemic changes: 10.0% vs. 5.3% 
et al. 1985 41 ↑ prevalence of rhythm disorders: 14% vs. 2.7%
Shcherbak Russia Lead workers 320 100 20–59 Job title NM Other workers ECG ↑ prevalence of ischemic changes: 11.6% vs. 6.7%
1988
Sroczynski Poland Lead workers 711 100 20–60 Job title NM Other workers ECG (Minnesota code) ↑ prevalence systolic murmur and rhythm disorders 
et al. 1990 ↑ prevalence ventricular repolarization
~ prevalence of ischemic changes
Gatagonova Russia Lead workers 500 78 20–60 Job title Mean Other workers Integral rehography Changes of intracardial and peripheral hemodynamics
1995a,b,d 67 Disorders of myocardial bioelectric activity and contractility
ECG ↑ P wave and QT, QRS interval; ~ P–Q interval
Gatagonova Russia Lead workers 68 100 NR Job title NM Other workers Exercise stress test ↑ prevalence of ischemic changes (↑ S-T segment > 1 mm 
1995c 15.9 vs. 4.2%)
Cheng et al. U.S. Normative 775 100 48–93 Blood Mean 5.79 Per 10 unit ↑ ECG Subjects < 65 years: ↑ QT, ↑ QRS interval for tibia and patella, 
1998 Aging Study ~ for blood 
Tibia Mean 22 µg/g Subjects ≥ 65 years: ~ QT, ~ QRS interval for all biomarkers 
Patella Mean 31 µg/g ~ conduction defects and arrhythmia for all biomarkers, indices 
and age groups, except ↑ intraventricular conduction defect 
for tibia lead in < 65 years
Studies of other vascular function abnormalities
Aiba et al. Japan Reﬁnery workers 48 100 18–69 Job title Mean 43.2 Correlation Acceleration  ↓amplitude ratio of the second/ﬁrst systolic wave (age adjusted) 
1999 plethysmography ~ amplitude ratio of the third/ﬁrst and third/ﬁrst waves (age 
adjusted) 
Abbreviations: ↑, ↓ – indicate increase or decrease (statistically signiﬁcant at p < 0.05, unless otherwise speciﬁed). BMI, body mass index; CI, conﬁdence interval; CV, coefﬁcient of vari-
ation; DB, deep breathe; ECG, electrocardiogram; exp., exposed; HF, high frequency; HRV, heart rate variability; LF, low frequency; NM, not measured; NR, not reported; NS, not signiﬁ-
cant; OR, odds ratio; pNN50, proportion of interval differences of successive normal-to-normal intervals > 50 msec; RMSSD, square root of the mean-squared differences of successive
NN intervals; SD, standard deviation; SDANN, SD of the average normal-to-normal interval. SDNN, SD of the normal-to-normal interval; TP, total power; US ultrasound; V, ventricular;
VLF, very low frequency.Discussion
Lead exposure and hypertension—sufficient
evidence to infer a causal relationship. Chronic
lead poisoning was connected to hypertension
in the 19th century (Lorimer 1886). With rare
exceptions (Vigdortchik 1935), a major limita-
tion of early reports was the lack of a com-
parison group (Sharp et al. 1987). The
hypertensive effects of lead have been exten-
sively documented in experimental animals
chronically exposed to high lead concentrations
and in workers chronically exposed to high
lead levels (Agency for Toxic Substances and
Disease Registry 1999; U.S. EPA 2006).
Generally, the development of hypertension in
subjects chronically exposed to high lead levels
has been interpreted as a possible consequence
of lead nephropathy. At environmental levels
of exposure, however, the effect of lead on
blood pressure has been controversial.
Numerous studies have addressed this ques-
tion. All reviews have concluded that there is
an association between lead and blood pres-
sure, although the strength of this association is
modest (Table 1). Substantial evidence, how-
ever, implies that this relationship is causal. 
Consistency. The association between
lead exposure and blood pressure has been
found in populations with different geo-
graphic, ethnic, and socioeconomic back-
ground. While residual confounding by
socioeconomic status is a concern, studies in
homogenous samples and studies that have
adjusted for a variety of socioeconomic indi-
cators have still identified an association
between lead exposure and blood pressure
(Martin et al. 2006; Pocock et al. 1984). 
Temporality. The association between
blood lead and elevated blood pressure has
been identiﬁed not only in cross-sectional but
also in prospective studies that showed that
new cases of hypertension and within-person
elevations in blood pressure levels over follow-
up were related to baseline lead exposure
(Glenn et al. 2003; Møller and Kristensen
1992; Weiss et al. 1986). 
Strength of the association. While the
strength of the association between lead and
blood pressure is modest, it may have been
substantially underestimated because of meas-
urement error in both lead and blood pressure
determinations. Most studies used single
blood lead measurements to assess lead expo-
sure. When bone lead was used as a bio-
marker of long-term exposure (Hu et al.
2007), lead in cortical or trabecular bone was
positively associated with increased systolic
blood pressure or hypertension in all prospec-
tive (Cheng et al. 2001; Glenn et al. 2003)
and cross-sectional studies (Gerr et al. 2002;
Hu et al. 1996; Korrick et al. 1999; Lee et al.
2001; Martin et al. 2006; Rothenberg et al.
2002; Schwartz and Stewart 2000).
Furthermore, even bone lead is subject to
error derived from the sampling site and from
the technical difﬁculties of the measurement.
In addition, blood pressure measurements
were often conducted using nonstandardized
protocols, without repeated measures, or in
samples including hypertensive subjects. 
Biologic gradient (dose response). Some
studies have demonstrated a progressive
dose–response relationship between lead expo-
sure and blood pressure (Pocock et al. 1984;
Schwartz 1988; Weiss et al. 1986). However,
the shape of the dose–response relationship is
not completely characterized, particularly at
low levels of exposure. It is not known what is
the lowest level of lead exposure not associated
with blood pressure, although in the available
studies there seems to be no evidence of a
threshold effect (Hertz-Picciotto and Croft
1993; Schwartz et al. 2001). 
Biologic plausibility and experimental
data. Numerous experimental studies in ani-
mals have shown irrefutable evidence that
chronic exposure to low lead levels results in
arterial hypertension that persists long after
the cessation of lead exposure (U.S. EPA
2006). The precise mechanisms explaining a
hypertensive effect of low chronic exposure to
environmental lead are unknown. An inverse
association between estimated glomerular ﬁl-
tration rate and blood lead has been observed
at blood lead levels < 5 µg/dL in general pop-
ulation studies (Ekong et al. 2006; Muntner
et al. 2005), indicating that lead-induced
reductions in renal function could play a
major role in hypertension. Other potential
mechanisms include enhanced oxidative stress
(Stohs and Bagchi 1995; Vaziri et al. 2001),
stimulation of the renin-angiotensin system
(Carmignani et al. 1999; Rodriguez-Iturbe
et al. 2005), and down-regulation of nitric
oxide (Ding et al. 1998; Dursun et al. 2005)
and soluble guanylate cyclase (Farmand et al.
2005). These mechanisms could result in
increased vascular tone and peripheral vascu-
lar resistance (U.S. EPA 2006).
Causal inference. We conclude that the
evidence is sufﬁcient to infer a causal relation-
ship between lead exposure and high blood
pressure. Further research is still needed to
determine the precise dose–response relation-
ship, the relative importance of short-term
versus chronic lead effects, the relevant mech-
anisms at environmental levels of exposure,
and whether the magnitude of the association
is different in children or in other vulnerable
population subgroups. 
Clinical cardiovascular end points in
general populations. Consistency and tem-
porality. Few cohort studies have evaluated
the prospective association of lead with
clinical cardiovascular outcomes in general
population settings. The findings of the
NHANES II and NHANES III Mortality
Follow-up studies are remarkable. NHANES
are periodic, standardized surveys designed to
provide representative health data from the
U.S. noninstitutionalized population.
Despite a marked decline in lead levels in
U.S. adults, both surveys showed statistically
signiﬁcant increases in cardiovascular mortal-
ity with increasing blood lead (Lustberg and
Silbergeld 2002; Schober et al. 2006). 
In addition a cross-sectional analysis of
NHANES 1999–2002 data identified an
association of blood lead with the prevalence
of peripheral arterial disease (Muntner et al.
2005; Navas-Acien et al. 2004). The British
Regional Heart Study (Pocock et al. 1988)
and two other small cohort studies
(Kromhout 1988; Møller and Kristensen
1992) showed positive but nonstatistically
signiﬁcant associations of coronary heart dis-
ease or stroke incidence with higher lead lev-
els. The confidence intervals from these
studies were wide but included the point esti-
mates of the NHANES studies. Additional
studies are needed to determine the consis-
tency of the evidence in diverse populations.
Strength of the association and dose
response. The associations of blood lead with
clinical cardiovascular end points in the
NHANES studies were moderately strong,
with a clear dose–response gradient. An unre-
solved issue is the impact of uncontrolled con-
founding and measurement error on the
relative risk estimates in studies of lead and
clinical cardiovascular end points. NHANES
studies adjusted for race, education, income,
and urban versus rural location, which reduces
potential confounding by socioeconomic sta-
tus. Studies with more detailed information on
the determinants of lead exposure may con-
tribute to a better understanding of this issue.
Similarly, evaluating lead effects using a single
blood lead measure may result in measurement
error with substantial underestimation of the
magnitude of the association. This is particu-
larly problematic when there are marked tem-
poral trends in lead levels, as this source of
error adds to within-person variability in blood
lead levels to increase regression-dilution bias. 
Biologic plausibility and experimental
data. Lead levels of 0.8 ppm (Revis et al.
1981) and 0.1 ppm (Minaii et al. 2002) in
drinking water induced atherosclerosis in ani-
mal models, and lead levels of 0.5–10 µM
induced the proliferation of vascular smooth
cells and fibroblasts in in vitro models
(Fujiwara et al. 1995). Lead-related athero-
sclerosis could be explained by several mecha-
nisms, including increases in blood pressure,
impairment of renal function (Ekong et al.
2006), and induction of oxidative stress
(Stohs and Bagchi 1995; Vaziri et al. 2001),
inflammation (Heo et al. 1996), and
endothelial dysfunction (Vaziri et al. 2001).
Causal inference. Because of the scarce
number of prospective studies and the lack of
Navas-Acien et al.
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information on incident nonfatal events, we
conclude that the evidence is suggestive but
not sufficient to infer a causal relationship
with clinical cardiovascular end points.
Prospective studies are required to character-
ize fully the impact of lead on cardiovascular
morbidity and mortality. These studies need
detailed and repeated assessment of lead expo-
sure and its determinants, standardized assess-
ment of traditional cardiovascular risk factors,
and long-term follow-up to identify incident
cardiovascular events and trends in subclinical
markers of atherosclerosis. Although elevated
blood pressure and impaired renal function
are proposed mechanisms that mediate the
effects of lead on clinical cardiovascular out-
comes, other mechanisms are likely to be
involved. Future epidemiologic studies should
explore in detail the magnitude of the contri-
bution of speciﬁc mediators of clinical cardio-
vascular lead effects.
Cardiovascular mortality in occupational
populations. Adequacy of the evidence. The
validity of occupational studies of lead and
cardiovascular mortality is limited by several
methodologic problems. A major limitation is
the healthy worker effect (Arrighi and Hertz-
Picciotto 1994). The comparison of exposed
workers with the general population is particu-
larly inappropriate for cardiovascular mortality
because workers are healthier and their
lifestyles and cardiovascular risk factors are
likely to differ widely from those of the general
population (Choi 1992). In addition, cardio-
vascular diseases are associated with prolonged
disability and changes in employment status.
Even in studies based on comparisons with
unexposed workers, the selection of healthier
individuals at time of hire or for speciﬁc jobs
within an industry may have resulted in biased
estimates of the association. Correcting the bias
introduced by the healthy worker survivor
effect is extremely challenging, and stratifying
by duration of employment or time since hire
is unlikely to completely account for this
source of bias (Arrighi and Hertz-Picciotto
1994; Howe et al. 1988). 
Additional limitations include the assign-
ment of lead exposure based on job titles and
of cardiovascular deaths based on death cer-
tificates. Misclassification of exposure and
outcome may have resulted in further under-
estimation of the association of lead and
cardiovascular end points. Finally, the lack of
determinations of established cardiovascular
risk factors and of other occupational expo-
sures may have contributed to uncontrolled
confounding. 
Causal inference. As a result of these
methodologic limitations, and despite many
occupational cohort studies published in the
literature (Table 3), available information on
occupational lead exposure and cardiovascular
mortality is inadequate to infer the presence or
absence of a causal relationship. Because stud-
ies of environmental lead exposure provide
evidence of an association between lead and
cardiovascular mortality at lower exposures
than those experienced by occupationally
exposed workers, we expect the impact of lead
in exposed workers to be at least as important
as in environmentally exposed subjects. 
Lead exposure and heart rate variability.
Consistency, temporality, and strength of
the association. Several studies, mostly cross-
sectional, found an association between
increased lead exposure and decreased heart
rate variability. The diversity in the methods
and conditions used for measuring heart rate
variability makes it difficult to compare the
association of lead exposure and heart rate
variability across studies. In addition, the
validity and precision of these studies are
often limited by small sample sizes, limita-
tions in the assessment of lead exposure, and
lack of control for established cardiovascular
risk factors and other confounders. 
Biologic plausibility and experimental
data. Lead, a well-established neurotoxicant,
could affect heart rate variability by interfer-
ing in autonomic nervous control of the
heart (Chang et al. 2005). Heart rate vari-
ability measures the fluctuation of the heart
rate around the mean heart rate (Task Force
of the European Society of Cardiology and
the North American Society of Pacing and
Electrophysiology 1996). Because the basis
of normal cardiac autonomic functioning is
the shift from parasympathetic to sympa-
thetic modulation, decreased heart rate vari-
ability is a marker of cardiac autonomic
dysfunction. Indeed, decreased heart rate
variability in supine position and in response
to postural change has been associated with
increased incident coronary heart disease and
all-cause mortality in large prospective
cohort studies in populations free of cardio-
vascular disease (Liao et al. 1997; Tsuji et al.
1996).
Causal inference. We conclude that the
evidence is suggestive of but not sufﬁcient to
infer a causal relationship of lead exposure
with heart rate variability. Large studies
with adequate measures of lead exposure and
Appendix A. Search strategy.
Databases: PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed); EMBASE (http://www.embase.com/); TOXLINE (http://toxnet.nlm.nih.gov/).
Free text and key word
Lead, lead poisoning, heavy metals, mortality, atherosclerosis, cardio-
vascular disease, peripheral arterial disease, peripheral vascular disease,
hypertension, blood pressure, heart rate, electrocardiogram, left ven-
tricular hypertrophy.
Search in PubMed
(Lead [MH] OR Lead poisoning [MH] OR (Metals, heavy [MH]
NOT (Actinium OR Americium OR Antimony OR Barium OR
Berkelium OR Bismuth OR Californium OR Cesium OR
Chromium OR Cobalt OR Copper OR Curium OR Einsteinium
OR Fermium OR Francium OR Gallium OR Germanium Gold OR
Hafnium OR Indium OR Iridium OR Iron OR Lawrencium OR
Manganese OR Molybdenum OR Neptunium OR Nickel OR
Niobium OR Nobelium OR Osmium OR Palladium OR Platinum
OR Plutonium OR Protactinium OR Radium OR Rhenium OR
Rhodium OR Rubidium OR Ruthenium OR Silver OR Strontium
OR Tantalum OR Technetium OR Thallium OR Thorium OR Tin
OR Tungsten OR Uranium OR Vanadium OR Zinc OR
Zirconium))) AND (Cardiovascular Disease [MH] OR Mortality OR
Myocardial Infarction OR Stroke OR Peripheral Arterial Disease OR
Peripheral Vascular Disease OR Hypertension OR Blood pressure OR
Systolic OR Diastolic OR Atherosclerosis OR Arteriosclerosis OR
Electrocardiography OR Heart Rate OR Ventricular Hypertrophy
OR heart failure)
Search in EMBASE
(Lead:de OR (Lead poisoning:de)) AND ((cardiovascular disease:de)
OR mortality:ti,ab OR (Myocardial Infarction:ti,ab) OR Stroke:ti,ab
OR (Peripheral Arterial Disease:ti,ab) OR (Peripheral Vascular
Disease:ti,ab) OR Hypertension:ti,ab OR (Blood pressure:ti,ab) OR
Systolic:ti,ab OR Diastolic:ti,ab OR Atherosclerosis:ti,ab OR
Arteriosclerosis:ti,ab OR Electrocardiography:ti,ab OR (Heart
Rate:ti,ab) OR (Ventricular Hypertrophy:ti,ab) OR (heart failure:ti,ab))
Search in TOXLINE
(Lead [MH] OR Lead poisoning [MH]) AND (Cardiovascular
Disease [MH] OR Mortality OR Myocardial Infarction OR Stroke
OR Peripheral Arterial Disease OR Peripheral Vascular Disease OR
Hypertension OR Blood pressure OR Systolic OR Diastolic OR
Atherosclerosis OR Arteriosclerosis OR Electrocardiography OR
Heart Rate OR Ventricular Hypertrophy OR heart failure)Navas-Acien et al.
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Appendix C. Criteria for evaluating the design and data analysis of epidemiologic studies of lead exposure and intermediate cardiovascular end points.a
Ventricular mass  Other
and function Heart rate variability Other cardiac abnormalities vasc.
Association estimates based on lead assessed at the individual  Y Y Y N N N Y N N Y N N N N N Y N N N N N N N Y N N N N N N Y Y
level
Association estimates based on blood or bone lead measures Y Y Y N N N Y Y N Y N N N N N Y N N N N N N N Y N N N N N N Y Y
Cardiovascular tests were based on a standardized protocol Y Y Y Y YYYYYYUYYYYYNNYNNNNYYYUYNNYN
Authors indicate that examiners received training to conduct  Y N Y N NNNNNNNNNNNNNNNNNNNYYNNNNNYU
cardiovascular tests 
Inclusion and exclusion criteria were similar for all participants Y U Y U Y Y Y N Y Y U Y N Y U Y U U U U U U N Y Y U Y U U U Y U
Recruitment procedures were similar for all participants  Y U Y U U Y Y Y N Y U U N Y U Y U U U U U U N Y Y U Y U U U Y U
Response rate was at least 70%  Y U N U U U U Y U U U U U U U U U U U U U U U Y Y U U U U U Y U
Examiner was blinded with respect to the participant exposure  Y U U U U U Y U U Y U U U U U Y U U U U U U U Y N U U U U U Y U
status
Authors controlled for relevant confounding factors in addition  Y Y Y N NNNNNNNNNNNNNNNNNNNYNNNNNNYN
to age, sex
Abbreviations: N, no; U, unclear; vasc., vascular; Y, yes; .
aCriteria modiﬁed from Appel et al. (2002). 
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Appendix B. Criteria for evaluating the design and data analysis of epidemiologic studies of lead exposure and clinical cardiovascular disease.a
General populations Occupational populations
Cohort studies CC and CS studies Prosp.  Retrospective cohort studies PMS
All studies
Lead exposure was assessed at the individual level Y Y Y Y Y Y Y Y N Y Y Y N N N N N N N N N N N N N N N N N Y
Exposure was assessed measuring lead levels in blood or bone Y Y Y Y Y N N N N N Y Y N N N N N N N N N N N N N N N N N N
Outcomes were based on objective tests/standard criteria in ≥ 9 0 % YYNNNNYYNNYYNNNNNNNNNNNNNNNNNN
of study participants
Authors presented internal comparisons within study participants Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N N N N N N N N N N N N Y Y
Authors controlled for relevant confounding factors in addition Y N Y Y Y N N N Y N N Y N N N N N N N N N N N N N N N N N N
to age and sexb
Cohort studies
Loss to follow-up was independent of lead exposure Y Y Y Y Y — — — — — — — Y N N N N N N N N N N N N N N N — —
Intensity of search of disease was independent of lead exposure Y Y Y Y Y — — — — — — — Y N N N N N N N N N N N N N N N — —
Case–control and cross-sectional studies
Response rate among noncases was at least 70% — — — — — N U Y U N U Y — — — — — — — — — — — — — — — — — —
Exclusion criteria and data collection were similar for all participants — — — — — U Y Y U U Y Y — — — — — — — — — — — — — — — — Y Y
Non cases would have been cases if they had developed — — — — — U N Y U U Y Y — — — — — — — — — — — — — — — — N N
cardiovascular disease
Interviewer was blinded with respect to the participant case or  — — — — — U U U U U U Y — — — — — — — — — — — — — — — — N N
exposure status
Abbreviations: —, not applicable; CC, case–control study; CS, cross-sectional study; N, no; PMS, proportional mortality study, Prosp., prospective; U, unclear; Y, yes. 
aCriteria modiﬁed from Longnecker et al. (1988). bIn occupational studies, relevant factors included the healthy worker survivor effect. Studies that adjusted for blood pressure levels
were considered not to fulﬁll this criterion.
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2standardized assessment of heart rate variabil-
ity are needed to better characterize the asso-
ciation between lead exposure and autonomic
cardiac control. 
Public health implications. The evidence
in this systematic review is sufﬁcient to infer a
causal relationship of lead exposure with ele-
vated blood pressure, and it is suggestive of
but not sufﬁcient to infer a causal relationship
of lead with clinical cardiovascular outcomes
and cardiovascular function tests. These asso-
ciations have been observed at blood lead
levels well below 5 µg/dL (Menke et al. 2006;
Nawrot and Staessen 2006). Indeed, no lower
threshold has been established for any lead-
cardiovascular association. 
Although future research will contribute to
characterize fully the impact of lead exposure
on cardiovascular health, these findings have
several important public health implications.
First, there is an immediate need to lower the
current safety standard of the World Health
Organization and the U.S. Occupational Safety
and Health Administration for blood lead in
workers (currently established at 40 µg/dL).
Second, a criterion for elevated blood lead levels
in adults needs to be established and screened
for in preventive services. In fact, the cardiovas-
cular end points described above plus the sub-
stantial evidence that chronic lead exposure
affects cognitive function (Shih et al. 2007) and
renal function (Ekong et al. 2006) at levels
< 5 µg/dL indicate that the U.S. Centers for
Disease Control and Prevention criterion for
elevated blood levels in children (10 µg/dL) is
too high for adults. Third, the hypertensive
effects of lead exposure and its impact on car-
diovascular mortality need to be included in
risk assessment and in economic analyses of
lead exposure impact. Finally, regulatory and
public health interventions must be developed
and implemented to prevent and reduce lead
exposure beyond current levels in adults. 
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